About EGRIFTA SV®?

EGRIFTA SV® is the only FDA approved treatment indicated for the reduction of excess abdominal fat in HIV-Infected adults patients with lipodystrophy.
EGRIFTA SV® specifically targets the visceral abdominal fat.

Mechanism of Action

Overview of the GH/IGF-1 axis1
  • Human growth hormone (GH) or somatropin is secreted by specialized cells called somatropes, which are located in the pituitary gland1
  • GH secretin is regulated by 2 hormones produced in the hypothalamus, with opposing effects1
    • Growth hormone-releasing hormone (GHRH), also known as growth hormone-releasing factor (GRF), increases production and pulsatile secretion of GH
    • Somatostatin counteracts the effects of GHRH and suppresses GH secretion
  • Endogenous growth hormone (GH) exerts its effects by interacting with specific receptors on target cells, including osteoblasts, myocytes and adipocytes, resulting in pharmacodynamic effects of anabolism and lipolysis2
  • GH secretion is also modulated by feedback mechanisms involving insulin-like growth factor-1 (IGF-1)
    • Produced mainly in the liver in response to GH
    • Appears to mediate many of the growth-promoting effects of GH
  • Rising levels of insulin-like growth factor-1 (IGF-1) exert a negative feedback effect on the secretion of growth hormone (GH)1

GH secretion
over time

    Learn More
  • EGRIFTA SV® is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the body to secrete its own growth hormone (GH) in a pulsatile release
    • In vitro, EGRIFTA SV® binds and stimulates GHRH receptors with similar potency as natural GHRH
  • GH plays an important role in the formation and function of fat cells as well as the overall regulation of fat metabolism2,3

*An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.

Growth hormone is not approved for the treatment of excess abdominal fat in patients with HIV with lipodystrophy.

Learn more about the proven efficacy of EGRIFTA SV®

References: 1. Longo DL, Fauci AS, Kasper DL, et al. Endocrinology and metabolism. In: Longo DL, Fauci AS, Kasper DL, et al., eds. Harrison’s Principles of Internal Medicine, Volume II. 18th ed. New York, NY: McGraw Hill Companies, Inc.; 2012:2890-2891. 2. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev. 2000;1(2):73-86. 3. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.